Hoth Therapeutics

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, Nov. 8, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc., (NASDAQ: HOTH) a patient focused biopharmaceutical company, announced today that it has entered into two contracts with STA Pharmaceutical, a subsidiary of WuXi AppTec (WuXi STA), for process development and manufacturing of the active pharmaceutical ingredient (API) and formulation of drug product for the continued development and commercialization of HT-KIT. HT-KIT is a new molecular entity (NME) morpholino oligonucleotide therapy in development for targeting mast cell-derived cancers (aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL)) and anaphylaxis.

Hoth Therapeutics Inks API and Drug Product Contracts with WuXi STA to Advance Manufacturing of HT-KIT Cancer Therapeutic

NEW YORK, Oct. 19, 2021 /PRNewswire/ --  Hoth Therapeutics, Inc . (NASDAQ: HOTH) has extended its partnership agreement with  REPROCELL to assess the effect of the HT-003 therapeutic platform in inflammatory bowel disease (IBD).

Hoth Therapeutics Extends Partnership Agreement with REPROCELL

NEW YORK, NY  / PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ:  HOTH ), a biopharmaceutical company, today announced that is has received Human Research Ethics Committee (HREC) clearance to commence cohort 2 of the Phase 1 clinical trial of BioLexa Lotion for the treatment of mild to moderate atopic dermatitis in Australia. BioLexa Trial Design:

Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis in Humans

NEW YORK, Oct. 12, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that is has received Human Research Ethics Committee (HREC) clearance to commence cohort 2 of the Phase 1b clinical trial of BioLexa Lotion for the treatment of mild to moderate atopic dermatitis in Australia.  BioLexa Trial Design: Randomized, double-blind, parallel-design, placebo-controlled study.

Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis Patients

NEW YORK, Sept. 21, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that a Safety Review Committee (SRC) has reviewed the safety data from the first cohort of healthy subjects and recommended that the study proceed to dosing patients with mild to moderate atopic dermatitis, also known as eczema.

Hoth Therapeutics Submits to Ethics Committee for Approval to Initiate Patient Cohort 2 in BioLexa Clinical Trial

NEW YORK, Sept. 8, 2021 /PRNewswire/ -- Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced the completed safety results in Cohort 1 of its first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as  eczema.

Hoth Therapeutics Announces Positive Phase 1b Results for Completed First Cohort of Patient Trial of BioLexa

NanoVibronix

Lordstown Motors

Which penny stocks are investors watching amid the SPRT stock short squeeze? The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 3 To Watch Amid SPRT Short Squeeze

NEW YORK, Aug. 11, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today highlights recent findings from North Carolina State University, that its new treatment for mast cell cancers, known as HT-KIT, reduces the number of mast cells by "mutating" the messenger RNA (mRNA) before it can deliver instructions for manufacturing the gene responsible for cell proliferation. "Current treatments for mast cell cancers target signaling from the receptor encoded by the c-KIT gene, and the efficacy of current therapies can be negatively affected by c-KIT mutations associated with disease development," says Glenn Cruse, assistant professor of immunology at North Carolina State University and a Scientific Advisor to Hoth and corresponding author of the research.

Hoth Therapeutics' mRNA 'Frameshifting' Therapy HT-KIT for Mast Cell Cancers Reduces Size, Spread - Research Published in Molecular Therapy

Hoth Therapeutics Inc (NASDAQ: HOTH) has initiated its preclinical study utilizing Hoth's HT-ALZ in an animal model. The study aims to determine the effects of HT-ALZ on behavioral and pathological markers of Alzheimer's disease and determine if HT-ALZ can improve learning and memory in an animal model of Alzheimer's disease.

Hoth Therapeutics Starts Preclinical Study For Its Alzheimer's Candidate

The stock price of Hoth Therapeutics Inc (NASDAQ: HOTH) increased by over 6% during intraday trading. This is why it happened.

HOTH Stock Increases Over 6% Intraday: Why It Happened

NEW YORK, Aug. 2, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has initiated its preclinical study utilizing Hoth's HT-ALZ in an animal model. The goal of the study is to determine the effects of HT-ALZ on behavioral and pathological markers of Alzheimer's disease and to determine if HT-ALZ can improve learning and memory in an animal model of Alzheimer's disease.

Hoth Therapeutics Initiates Preclinical Study of HT-ALZ for Alzheimer's Disease

Hoth Therapeutics Inc (NASDAQ: HOTH) has announced that its HT-003 group of assets has yielded positive results in an in vivo acne therapeutic model.  The model showed that HT-003 reduces toll-like receptor 2 (TLR2) expression, one of the most critical pathways for acne pathophysiology.

Hoth Therapeutics' HT-003 Shows Encouraging Action Against Acne In Animal Model

NEW YORK, July 13, 2021 /PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that its HT-003 group of assets has yielded positive results in an in vivo acne therapeutic model. The model showed that HT-003 reduces the expression of toll-like receptor 2 (TLR2), one of the most critical pathways for acne pathophysiology.

Hoth Therapeutics Announces Positive Confirmatory Results from In Vivo Model of HT-003 Assets as Potential Treatment Against Acne

NEW YORK, June 28, 2021 /PRNewswire/ -- Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced the safety results in Cohort 1 of its first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema. BioLexa has been administered twice per day for 14 days to the first ten subjects within Cohort 1; The interim safety review indicates that BioLexa was well tolerated with no serious adverse events and no drug-related treatment-emergent adverse events observed.

Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis

NEW YORK, June 7, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  today announced that it has entered into a Sponsored Research Agreement with Washington University in St. Louis to support the continued research and development of HT-ALZ , a novel therapeutic for the treatment of symptoms related to Alzheimer's disease. The research will be led by Carla Yuede, PhD, Associate Professor of Psychiatry, and John Cirrito, PhD, Associate Professor of Neurology, at Washington University School of Medicine.

Hoth Therapeutics Announces Sponsored Research Agreement with Washington University for Novel Alzheimer's Therapeutic HT-ALZ

Hoth Therapeutics Inc (NASDAQ: HOTH) has reported results from a preclinical trial of HT-KIT, a new molecular entity under development to treat mast cell-derived cancers and anaphylaxis. HT-KIT is an mRNA frame-shifting therapeutic designed to specifically target the receptor tyrosine kinase KIT, which is required for the proliferation, survival, and differentiation of bone marrow-derived hematopoietic stem cells.

Hoth Therapeutics Unveils Preclinical Results of HT-KIT Therapeutic Program

NEW YORK, June 3, 2021 /PRNewswire/ --  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it will share positive results from a preclinical trial during its shareholder presentation, reinforcing the potential of HT-KIT , a new molecular entity under development for treatment of mast cell-derived cancers and anaphylaxis. HT-KIT is an mRNA frame-shifting therapeutic designed to specifically target the receptor tyrosine kinase KIT, which is required for the proliferation, survival and differentiation of bone marrow-derived hematopoietic stem cells.

Hoth Therapeutics Shares Positive Preclinical Results of Novel HT-KIT Therapeutic

NEW YORK, June 1, 2021 /PRNewswire/ --  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today plans to host a virtual information session on its pipeline product, HT-KIT , a new molecular entity under development for treatment of mast cell-derived cancers and anaphylaxis, on Thursday, June 3rd for interested shareholders. Dr. Glenn Cruse, Ph.D.

Hoth Therapeutics Plans Shareholder Presentation on HT-KIT Therapeutic's Preclinical Results for Rare Cancers

NEW YORK, May 24, 2021 /PRNewswire/ --  Hoth Therapeutics , Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it will be an exhibitor at the American Society of Clinical Oncology (ASCO) Annual Meeting. Attendees will be able to visit the Hoth Therapeutics booth virtually starting May 24th through July 6, 2021.

Hoth Therapeutics Announces Participation at the American Society of Clinical Oncology (ASCO) Annual Meeting

HOTH Therapeutics was one of the sponsors for the Benzinga Biotech Small Cap Conference that took place on March 24-25, 2021. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only.

HOTH Therapeutics (NASDAQ: HOTH): Developing Life-Changing Drugs for Rare Cancers and Diseases

NEW YORK, May 13, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  announced today it plans to host a virtual information session on its pipeline product, HT-005 Z-Pods™ , a novel endocannibinoid treatment for patients with Cutaneous Lupus Erythematosus (CLE), on Tuesday, May 18th at 11:00am ET for interested shareholders. Adam Friedman, MD, FAAD and Professor and Chair of Dermatology at George Washington School of Medicine and Health Sciences, who has worked on the development of this novel therapeutic, will provide an overview on the burden of cutaneous lupus, the gap in care for diagnosed patients, and how HT-005 Z-Pods™ is designed to address both treatment and quality of life concerns for CLE patients.

Hoth Therapeutics Provides Shareholder Update on Novel Endocannabinoid Therapeutic for Cutaneous Lupus Erythematosus

NEW YORK, May 5, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has expanded its sponsored research agreement with Virginia Commonwealth University (VCU) for a potential COVID-19 treatment. Based on positive preclinical results generated by Dr. Michael Peters against COVID-19 using live virus inhibition assays, Hoth has amended its original scientific agreement with VCU and has agreed to further develop Dr.  Peters's novel peptide COVID-19 Therapeutic, HT-002.

Hoth Therapeutics and Virginia Commonwealth University Expand Research Agreement for COVID-19 Therapeutic

NEW YORK, May 3, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a patient-focused clinical-stage biopharmaceutical company, announced it intends to pursue development of its HT-KIT mRNA Frame Shifting Therapeutic for multiple orphan diseases, which are rare diseases that affect less than 200,000 people in the US. HT-KIT targets a shared cell signaling pathway that may have therapeutic potential for multiple rare cancers, including: Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL) Acute myeloid leukemia (AML) Gastrointestinal stromal tumors Drugs intended to treat orphan diseases are eligible to apply for Orphan Drug Designation (ODD), which provides multiple benefits to the sponsor during development and after approval.

Hoth Therapeutics Announces Development of HT-KIT to Treat Multiple Orphan Diseases, Including Rare Cancers

NEW YORK, April 22, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce the start of its First in Human clinical trial investigating topical BioLexa for the treatment of mild to moderate atopic dermatitis, also known as eczema. "We are excited to have reached this pivotal milestone in our BioLexa development program," stated Robb Knie, CEO of Hoth Therapeutics.

Hoth Therapeutics' First in Human Clinical Trial for the Treatment of Atopic Dermatitis with BioLexa is Underway

Hoth Therapeutics Inc (NASDAQ: HOTH) has reported that its novel anti-cancer therapeutic demonstrated positive results in humanized mast-cell neoplasm animal models for aggressive, mast cell-derived cancers such as mast cell leukemia and mast cell sarcoma. The anti-cancer therapeutic, currently in development, uses mRNA frameshifting that induces apoptosis of neoplastic mast cells and cell death in neoplastic mast cells.

News for Hoth Therapeutics Stock (HOTH)